ABUS News and Press, Arbutus Biopharma Corporation From 03/27/25

2025-03-27 09:03:00 ET More on Arbutus Biopharma Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr. Arbutus: Positive Imdusiran Data Leads To Phase 2B Development Arbutus appoints Lindsay Androski as CEO Arbutus expects to significantly reduce its net ...

2025-03-27 08:01:11 ET More on Arbutus Biopharma Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr. Arbutus: Positive Imdusiran Data Leads To Phase 2B Development Arbutus appoints Lindsay Androski as CEO Arbutus expects to significantly reduce its net ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September 2025 Reviewing pipeline and development plans for HBV programs Continued foc...

HG Holdings Inc (STLY) is expected to report for quarter end 2024-12-31 Savara Inc. (SVRA) is expected to report $-0.11 for Q4 2024 Reborn Coffee Inc. (REBN) is expected to report for quarter end 2024-12-31 VSee Health Inc. (VSEE) is expected to report for Q4 2024 IceCure Medical ...

Papaya Growth Opportunity Corp. I (PPYA) is expected to report for quarter end 2024-12-31 KinderCare Learning Companies Inc. (KLC) is expected to report $0.04 for Q4 2024 Recordati SpA (RCDTF) is expected to report for quarter end 2024-12-31 InflaRx N.V. (IFRX) is expected to report $...

2025-03-13 10:23:42 ET Arbutus Biopharma Corporation (NASDAQ: ABUS) has caught the attention of the investment community today with its bullish price action. The company’s shares have moved 5.17% on the day to $3.35. Arbutus Biopharma Corporation, a biopharmaceutical company,...

Team Inc. (TISI) is expected to report for quarter end 2024-12-31 Chesswood Group Limited (CHWWQ) is expected to report for Q4 2024 J. W. Mays Inc. (MAYS) is expected to report for Q2 2025 Allakos Inc. (ALLK) is expected to report $-0.17 for Q4 2024 Aurora Mobile Limited (JG) is e...

Air France-KLM ADR (AFLYY) is expected to report $0.02 for Q4 2024 Viracta Therapeutics Inc. (VIRX) is expected to report for Q4 2024 BJ's Wholesale Club Holdings Inc. (BJ) is expected to report $0.89 for Q4 2025 Deutsche Lufthansa AG ADR - Level I (DLAKY) is expected to report $0.22 ...

BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio (a subsidiary of Roivant Sciences, Ltd. (Nasdaq: ...

2025-02-25 08:39:33 ET More on Arbutus Biopharma Arbutus, Burford Capital, And Cadiz With Chris DeMuth Jr. Arbutus: Positive Imdusiran Data Leads To Phase 2B Development Arbutus expects to significantly reduce its net cash burn in 2025 Arbutus could benefit f...